Dermatol Surg
December 2024
Department of Dermatology, Baylor Scott & White Medical Center, Temple, Texas.
Int J Dermatol
December 2024
Division of Dermatology, Baylor University Medical Center, Dallas, Texas, USA.
Bone Marrow Transplant
December 2024
The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Gastroenterology
November 2024
Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, California. Electronic address:
Background & Aims: Currently, patients with hepatocellular carcinoma (HCC) in the United States are assigned a uniform score relative to the median Model for End-Stage Liver Disease (MELD) at transplant after a minimum 6-month waiting period. The authors developed a risk stratification model for patients with HCC using the available and objective variables at time of listing.
Methods: Adult liver transplant candidates with approved HCC exception in the Organ Procurement and Transplantation Network database from 2015-2022 were identified.
J Arthroplasty
November 2024
Department of Orthopedic Surgery, University of Pennsylvania Health System, Philadelphia, Pennsylvania.
Background: There is a scarcity of literature concerning individuals who have existing post-traumatic stress disorder (PTSD) and their outcomes after primary total knee arthroplasty (TKA). This study compared outcomes in patients undergoing primary TKA who have a previous history of PTSD.
Methods: An electronic health care database was used to identify patients diagnosed with PTSD undergoing TKA.
Curr Rev Musculoskelet Med
November 2024
The Carrell Clinic, Dallas, TX, USA.
Purpose Of Review: Femoroacetabular impingement (FAI) with labral tear is an increasingly recognized source of hip pain and lost playing time in elite athletes, yet data pertaining to professional American football athletes remains scarce. Prognostic recommendations are largely limited to single-institution cohort studies. To date, no large-scale literature review of surgical treatment of FAI in elite American football athletes has been performed.
View Article and Find Full Text PDFHead Neck Pathol
November 2024
Texas A&M University School of Dentistry, Dallas, USA.
Am J Cardiol
November 2024
Department of Cardiac Surgery, Baylor University Medical Center, Dallas, Texas. Electronic address:
A congenitally malformed aortic valve, unicuspid (UAV), or bicuspid (BAV), occurs in about 1% of the population and is known to be more frequent in patients with aortic dissection. The clinical and operative findings in a series of 134 patients with spontaneous, acute type A aortic dissection were studied, comparing patients with normal and abnormal aortic valve morphology. The aortic valve was normal in 123 of 134 (92%) patients and abnormal in 11 of 134 (8%) patients: BAV in 10 of 134 (7.
View Article and Find Full Text PDFJ Pediatr
November 2024
Pediatrix Center for Research Education, Quality, and Safety, Sunrise, FL; Division of Neonatology, Department of Pediatrics, Baylor University Medical Center, Dallas, TX; Pediatrix Medical Group, Dallas, TX.
Objective: To describe the trends in percentage oxygen requirement and mode of respiratory support delivered to extremely premature infants in the 12 weeks after birth.
Study Design: This is a retrospective study of extremely premature infants (≤27 weeks) discharged from neonatal intensive care units managed by Pediatrix Medical Group between January 1, 2016, and December 31, 2021. Demographic and daily clinical data (mode of respiratory support and fraction of inspired oxygen [FiO]) were extracted from the Pediatrix Clinical Data Warehouse.
BMJ Open
November 2024
Department of Surgery and Perioperative Care, The University of Texas at Austin Dell Medical School, Austin, Texas, USA
Objective: This qualitative study aimed to analyse rectal cancer survivors' lived experiences to identify facilitators and barriers to support access.
Design: We conducted one-on-one semi-structured interviews and employed thematic analysis to identify key themes and insights.
Setting/participants: Participants included eight rectal cancer survivors and three caregivers recruited at Texas Colorectal Collaborative sites.
JACC Heart Fail
January 2025
Harvard Medical School, Boston, Massachusetts, USA; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Background: Lower estimated glomerular filtration rate (eGFR) may be one of the major reasons for hesitation or failure to initiate potentially beneficial therapies in patients with heart failure (HF).
Objectives: This study sought to assess if the effects of sacubitril/valsartan (vs valsartan) on cardiovascular outcomes differ according to baseline kidney function in patients with HF with preserved ejection fraction.
Methods: The PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction) trial was global clinical trial of 4,796 patients with chronic HF and left ventricular ejection fraction (LVEF) ≥45% randomly assigned to sacubitril/valsartan or valsartan.
J Am Coll Cardiol
November 2024
Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas and Imperial College, London UK.
Catheter Cardiovasc Interv
November 2024
Department of Cardiology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Gut
November 2024
Center for Gastrointestinal Research; Center from Translational Genomics and Oncology, Baylor Scott & White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA
Background: There is no clinically relevant serological marker for the early detection of oesophageal adenocarcinoma (EAC) and its precursor lesion, Barrett's oesophagus (BE).
Objective: To develop and test a blood-based assay for EAC and BE.
Design: Oesophageal MicroRNAs of BaRRett, Adenocarcinoma and Dysplasia () was a large, international, multicentre biomarker cohort study involving 792 patient samples from 4 countries (NCT06381583) to develop and validate a circulating miRNA signature for the early detection of EAC and high-risk BE.
J Surg Educ
January 2025
Massachusetts General Hospital, Department of Surgery, Boston, Massachusetts.
Circulation
November 2024
Baylor University Medical Center, Dallas, TX and Imperial College, London, UK.
Background: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical endpoints, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden in these patients.
Methods: 731 patients in class II-IV heart failure, ejection fraction ≥50%, and body mass index ≥30 kg/m were randomized(double-blind) to tirzepatide(titrated up to 15mg subcutaneously weekly)(n=364) or placebo(n=367), added to background therapy for a median of 104 weeks (Q1=66, Q3=126 weeks).
N Engl J Med
November 2024
From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.); Flourish Research, Boca Raton, FL (S.J.B.); the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland (V.M.); the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China (J.G.); Eli Lilly, Indianapolis (G.J.W., Y.O., M.C.B., K.C.H., M.M.); and the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
Background: Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes.
Methods: In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks.
Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) display circulatory volume expansion and pressure overload contributing to cardiovascular-kidney end-organ damage. In the SUMMIT trial, patients with HFpEF and obesity were randomized to the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist tirzepatide (n = 364, 200 women) or placebo (n = 367, 193 women). As reported separately, tirzepatide decreased cardiovascular death or worsening heart failure.
View Article and Find Full Text PDFAm J Surg
November 2024
Division of Surgical Oncology, Baylor University Medical Center, Dallas, TX, USA; Texas A&M University School of Medicine, Dallas, TX, USA. Electronic address:
Arch Dermatol Res
November 2024
Department of Pediatrics, Burnett School of Medicine, Texas Christian University, TCU Box 297085, Fort Worth, TX, 297086, USA.
Case Rep Oncol
November 2024
Department of Internal Medicine, Baylor Scott & White Medical Center, Temple, TX, USA.
J Am Acad Dermatol
November 2024
Division of Dermatology, Baylor University Medical Center, Dallas, Texas; Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas; Epiphany Dermatology, Dallas, Texas; Department of Dermatology, University of Texas at Southwestern, Dallas, Texas. Electronic address:
Gastroenterology
November 2024
Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address:
Background & Aims: Hepatocellular carcinoma (HCC) risk stratification is an urgent unmet need for cost-effective HCC screening and early detection in patients with cirrhosis to improve poor HCC prognosis.
Methods: Molecular (prognostic liver secretome signature with α-fetoprotein) and clinical (aMAP [age, male sex, albumin-bilirubin, and platelets] score) variable-based scores were integrated into PAaM (prognostic liver secretome signature with α-fetoprotein plus age, male sex, albumin-bilirubin, and platelets), which was subsequently validated in 2 phase 3 biomarker validation studies: the statewide Texas HCC Consortium and nationwide HCC Early Detection Strategy prospective cohorts, following the prospective specimen collection, retrospective blinded evaluation design. The associations between baseline PAaM and incident HCC were assessed using Fine-Gray regression, with overall death and liver transplantation as competing events.
Am J Transplant
November 2024
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
© LitMetric 2025. All rights reserved.